Salazar-Ortiz DY, Miranda-Rodríguez JA, Contreras-Carreto NA

Language: Spanish
References: 12
Page: 696-703
PDF size: 524.54 Kb.

ABSTRACT

Objetive: To compare the efficacy of letrozole vs. clomiphene citrate (CC) in women with infertility due to Polycystic Ovary Syndrome (PCOS) treated at the Hospital for Women.
Material and Methods: Single prospective randomized study in patients with PCOS who were given inducing ovulation and monitoring was performed by transvaginal ultrasound on 6, 9 and 12 of the menstrual cycle to assess follicular and endometrial growth and success with pregnancy.
Results: The groups were composed of 24 patients, 31.7 ± 5.7 years. Group A was composed of 12 patients for treatment with letrozole and 12 patients with CC to the B group. Number of cycles to achieve pregnancy group 1.3 ± 0.5 and 1.1 ± 0.4 in group B (ME ± SD); number of schemes to achieve pregnancy group ± 1.2 0.4 ± 1.1 and 0.4 group B; endometrial growth group 1.8 ± 8.7, 8.2 ± 0.9 in group B and pregnancy success 16.6% for group A, and 0% for group B. Number of cycles to achieve pregnancy (p = 0.07); number of schemes to achieve pregnancy (p = 0.33); follicular growth (p = 0.28); greater number of follicles produced in the cycle (p = 0.46); endometrial growth (p = 0.03), pregnancy success (p = 0.01).
Conclusion: Letrozole had no more efficacious than CC who despite having presented a lower endometrial growth achieved success with pregnancy.

REFERENCES

1. Batiza R, Carmona I, Campos J. Diagnóstico y tratamiento de la anovulación. Ginecol Obstet Mex 2011;79(11):683-696.

2. Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil. Steril. 2006;85:277-284.

3. Mitwally M, Casper R. Use of aromatase inhibitor for ovulation induction in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75(2): 305-309.

4. Baruah J, Roy KK, Rahman SM, Kumar S, Sharma JB, Karmakar D. Endometrial effects of letrozole and clomiphene citrate in women with polycystic ovary syndrome using spiral artery Doppler. Archives of Gynecology & Obstetrics 2009;279:311-314.

5. Inhibidores de la aromatasa para pacientes subfértiles con síndrome de ovario poliquístico (Revision Cochrane traducida). Cochrane Database of Systematic Reviews 2014 Issue 2. Art. No.: CD010287. DOI: 10.1002/14651858. CD010287

6. Meta-análisis de letrozol frente al citrato de clomífero en el síndrome de ovario poliquístico. Biomedicina Reproductiva Online. 2011;23(1):91-96.

7. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004;81:19-25

8. Garcia J, Jones GS, Wentz AC. The use of clomiphene citrate. Fertil Steril. 1977;28:707-717.

9. Duarte J,Mijangos J, Barragan J, Diaz S, Castro V. Síndrome de hiperestimulación ovárica. Rev de la Asociación Mexicana de Med Crítica y Terapia Intensiva. 2007;21(3):135-142.

10. Van Rumste M, Custers I, Van der Veen F, Van Wely M, Evers J, Mol B. The influence of the number of follicles on pregnancy rates in intrauterine insemination with ovarian stimulation: a meta-analysis. Hum Reprod Update 2008; 14: 563-570.

11. Góngora RA. El endometrio es determinante para lograr mejores tasas de embarazo en inseminación intrauterina. Rev Fac Med UNAM 2007;50(1):10-13.

12. Forman R, Gill S, Moretti M, Tulandi T, Koren G, Casper R. Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynecol Can 2007;29:668-671.